Drug-labels.com

Latisse: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
0.03 %
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Latisse

What is LATISSE used for?

  • LATISSE is used to treat hypotrichosis (less than normal hair) of the eyelash to increase the length, thickness and darkness of eyelashes.

How does LATISSE work?

LATISSE is believed to lengthen the growth period of your eyelashes and increasing the number of lashes involved in the growth phase. This results in longer, fuller and darker eyelashes.

What are the ingredients in LATISSE?

Medicinal ingredients: bimatoprost

Non-medicinal ingredients: benzalkonium chloride as preservative, citric acid monohydrate, sodium chloride, sodium phosphate dibasic heptahydrate and purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH.

LATISSE comes in the following dosage forms:

Topical solution 0.03%, w/v

Do not use LATISSE if:

  • You are allergic to bimatoprost, to any of the other ingredients, or to any of the parts of the container (see section What are the ingredients in LATISSE?).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take LATISSE. Talk about any health conditions or problems you may have, including if you:

  • have no visible eyelashes. Your doctor will consider any underlying conditions to determine whether this product is appropriate for you
  • are taking, or have recently taken, any other medicines. Using LATISSE with other medicines or bimatoprost products may reduce their effectiveness.
  • are pregnant or are planning to become pregnant

  • are breastfeeding or planning to breastfeed. Ask your doctor about how to feed your baby while using LATISSE.
  • have an active eye infection, inflammation (e.g. uveitis) or any other eye or eyelid condition
  • need to have eye surgery

Other warnings you should know about:

Changes in eye and eyelid colour:

LATISSEuse has been associated with iris pigmentation (change in the coloured part of the eye). This is likely to be permanent. To help avoid pigmentation, it is extremely important to strictly observe the following measures:

  • Do not apply directly in the eye.
  • Do not add more than one drop to an applicator.
  • Blot any excess solution outside the upper eyelid margin with a tissue or other absorbent material.
  • Do not administer the medication more than once daily.
  • Do not apply to the lower eyelash line.
  • Do not use the same applicator for more than one eye.
  • Do not reuse applicators.
  • Do not alter the applicator in any form.
  • Do not use any other brush/applicator to apply LATISSE.

Using too much LATISSE may contribute to iris pigmentation. LATISSE use may also cause darkening of the eyelid skin which may be reversible in most patients (see Overdose section).

Hair growth:

It is possible for hair growth to occur in other areas of your skin that LATISSE frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE.

Changes in vision:

Application of LATISSE may temporarily blur your vision. Do not drive or use machines until your vision has cleared.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

If you are using LUMIGAN or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IP, you should only use LATISSE under the close supervision of your doctor.

The following may interact with LATISSE:

No specific drug interaction studies have been done with this medication.

How to take LATISSE:

  • DO NOT APPLY in your eye or to the lower lid. ONLY use the sterile applicators supplied with

    LATISSE to apply the product. Do not reuse or modify applicators and do not use any other brush/applicator to apply LATISSE. Fifty percent of patients treated with LATISSE in a clinical study saw significant improvement by 2 months after starting treatment.

  • If LATISSE solution from a single dose gets into the eye, it is not expected to cause harm. Don’t allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination by common bacteria known to cause infections.
  • LATISSE contains a preservative called benzalkonium chloride which may discolour soft contact lenses if the eye is exposed. If you wear contact lenses, remove them before using LATISSE. They may be reinserted 15 minutes after LATISSE application.
  • Always use LATISSE exactly as your doctor has instructed you.

Follow these steps to use LATISSE properly:

  • Clean your face and ensure that makeup and contact lenses are removed (see Illustration 1).
  • Remove an applicator from its tray. Then, holding the sterile applicator horizontally, place ONLY one drop of LATISSE on the area of the applicator closest to the tip but not on the tip (see Illustration 2).
  • Immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part (see Illustration 3).
  • Blot any excess solution beyond the eyelid margin (see Illustration 4).
  • Dispose of the applicator after one use (see Illustration 5).
  • Repeat for the opposite upper eyelid margin using a NEW sterile applicator. This helps minimize any potential for contamination from one eyelid to another.

Illustration 1: Ensuring your face is clean

Illustration 2: Properly applying the drop to the unmodified applicator

Illustration 3: Applying LATISSE to the upper eyelid margin using the unmodified applicator provided Illustration 4: Blotting any excess solution

Illustration 5: Dispose of the applicator

Usual dose:

The recommended dosage is one application nightly to the skin of the upper eyelid margin of each eye at the base of the eyelashes only.

Use of LATISSE more than once a day is not expected to increase the growth of eyelashes more than use once a day.

Overdose:

Overdosing (putting more than one drop on the applicator) may result in an increased chance of iris pigmentation (IP). Any extra solution outside the upper lid margin should be blotted with a tissue. If LATISSE solution from a single dose gets into your eyes, it is not expected to cause harm.

If you think you, or a person you are caring for, have taken too much LATISSE, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, don’t try to “catch up.” Just apply LATISSE solution the next evening. Do not double dose.

What are possible side effects from using LATISSE?

These are not all the possible side effects you may have when taking LATISSE. If you experience any side effects not listed here, tell your healthcare professional.

Like all medicines, LATISSE can have side effects. Most of the side effects are not serious.

The most common side effects after using LATISSE solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSEsolution may cause other less common side effects which typically occur on the skin close to where LATISSE is applied, or in the eyes. These include skin darkening, iris pigmentation, eye irritation, peeling of skin, deepening and drooping of the eyelid, dryness of the eyes and redness of the eyelids.

Serious side effects and what to do about them

Symptom / effectTalk to your healthcareStop taking drug
professionaland get
Only if severeIn all casesimmediate
medical help
UNKNOWN FREQUENCY
New ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity (vision), have ocular (eye) surgery, or develop any ocular reactions, particularly conjunctivitis (eyelid infection) and eyelid reactions√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

LATISSE should be stored in the original container at 2° to 25°C.

Do not use the drops after the expiry date (marked “Exp”) on the bottle and the box.

Keep out of reach and sight of children.

If you want more information about LATISSE:

  • Talk to your healthcare professional.
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (www.canada.ca/en/health- canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website www.abbvie.ca, or by calling 1-888-704-8271.

Last Revised AUG 25, 2022

© 2022 AbbVie. All rights reserved.

LATISSE and its design are trademarks of AbbVie Corporation.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02350939

Revision date stated in the text: August 25, 2022

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Latisse

Rx or OTC
Prescription (Rx)?
DIN 02350939
Schedule(s) PRESCRIPTION
Active ingredient(s) Bimatoprost 0.03 %
Dosage form(s) Solution
Route(s) of administration Topical
Drug class (WHO ATC)
  1. S Sensory organ drugs
    1. S01 Ophthalmologicals
      1. S01E Antiglaucoma preparations and miotics
        1. S01EE Prostaglandin analogues, antiglaucoma drugs and miotics
          1. S01EE03 Bimatoprost
Company ABBVIE CORPORATION
Current status Marketed
Current status date June 21, 2024

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.